Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) at the end of treatment (EOT) and 24 weeks af...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
chronic hepatitis B
therapeutic vaccine
sustained effects
nasal vaccine
NASVAC
HBsAg/HBcAg vaccine
Medicine
R
Acceso en línea:https://doaj.org/article/2121e5c663214e4da03bd2d7a3be6939
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2121e5c663214e4da03bd2d7a3be6939

Ejemplares similares